Tuesday, June 1, 2010

Vitalea Science Announces Key Addition to its Scientific Advisory Board in Microdosing for Pediatric Pharmacology and HIV Research

Vitalea Science Announces Key Addition to its Scientific Advisory Board in Microdosing for Pediatric Pharmacology and HIV Research

Vitalea Science announces the addition of Dr. Edmund Capparelli to its Scientific Advisory Board. Dr. Capparelli is a leading HIV and pediatric pharmacologist at the University of California, San Diego (UCSD). He is Director of the UCSD Pediatric Pharmacology Research Unit, which focuses on protocols to safely evaluate drugs for pediatric populations. Vitalea's microdosing technology enables a patient-friendly, FDA-endorsed approach to safely evaluate drugs in a wide range of patients, with specific advantages for pediatric drugs.

Woodland, CA (PRWEB) May 10, 2007

Vitalea Science, Inc., a privately held company that improves and accelerates clinical drug development by measuring drug metabolism in humans earlier than ever before possible, today announced the addition of Edmund Capparelli to its Scientific Advisory Board (SAB).

As a distinguished leader in HIV and pediatric pharmacology, Dr. Capparelli will assist Vitalea in developing tools for pediatric clinical pharmacology using Vitalea's Accelerator Technology, particularly in clinical trials for HIV/AIDS and related infections.

Pediatric drug development poses special challenges to pharmaceutical and biotechnology companies. Children's ability to metabolize drugs differs from adults, making it risky to simply extrapolate drug performance results from adults to children. Plus, the need for stringent safety requirements for newborns and children make it difficult to use current technology to adequately study drugs in pediatric populations. As a result, drugs are often used in children without a complete understanding of their performance characteristics, and only five of the 80 drugs most frequently used in newborns and infants have FDA-approved labels for pediatric use.

Dr. Capparelli is Clinical Professor in the Pediatrics Division of Pharmacology and Drug Discovery of the Skagg's School of Pharmacy & Pharmaceutical Sciences, School of Medicine, University of California, San Diego (UCSD), and Director of the UCSD Pediatric Pharmacology Research Unit (PPRU), which is part of a national network of thirteen research centers focused on child-friendly clinical research protocols to safely evaluate drugs for pediatric populations.

He is also Director of the UCSD Pharmacology Laboratory for the International Maternal, Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) network. Board certified in Applied Pharmacology, Dr. Capparelli holds appointments with the UCSD Schools of Medicine and Pharmacy. He is recognized for his work in applying population pharmacokinetic methods in pediatric populations. Dr. Capparelli has served on the Advisory Sub-Committee to the FDA in Clinical Pharmacology, NIH workshop panels, the editorial board for Antimicrobial Agents and Chemotherapy, and the World Health Organization expert working group on Pediatric HIV/AIDS.

"I am delighted to have a person with Dr. Capparelli's experience in Pediatric Pharmacology and HIV therapeutic evaluations join our Scientific Advisory Board," said Le Vuong, Vitalea's Co-founder and Chief Operating Officer. "Edmund will be a tremendous asset to Vitalea's efforts to bring new tools to pediatric pharmacology."

In February, 2007 Vitalea announced a grant award from the National Institute of Allergy and Infectious Diseases (NIAID) to develop and test assays to quantify intracellular uptake of the active metabolite of a nucleoside reverse transcriptase inhibitor (NRTI) drug that can be applied to children and neonates. Dr. Capparelli will play a key role in the implementation of these assays.

"I greatly appreciate the opportunity to join the scientific board of such an entrepreneurial and innovative organization as Vitalea," said Edmund Capparelli. "Pediatric drug development is in desperate need of new technologies to safely evaluate drugs in our most vulnerable populations. Vitalea's technology capabilities offer the opportunity to safely test key pharmacokinetic and metabolism characteristics in pediatric populations, giving us valuable insight into drug selection and dosing for infants and children that is not available with current methods."

About Vitalea Science (http://www. vitaleascience. com (http://www. vitaleascience. com))
Vitalea Science is a leading contract research organization that provides ultra-sensitive detection strategies for drugs and drug candidates at microdose levels. Situated in Northern California, the company was formed by chemists and physicists from the University of California and the Department of Energy's Lawrence Livermore National Laboratory in 2003.

###